硕迪生物 GPCR 深 沪
等待开盘 04-02 09:30:00 美东时间
50.17
+1.970
+4.09%
华盛通- 最 高52.47
- 今 开49.46
- 成交量 135.61万股
- 最 低 48.84
- 昨 收 48.20
- 总市值 35.54亿
- 52周最高 94.90
- 市盈率 静 --
- 换手率 1.91%
- 52周最低 15.80
- 委 比 13.42%
- 总股本 7084.18万
- 历史最高 94.90
- 量 比 1.28
- 振 幅 7.53%
- 历史最低 13.22
- 每 手 1
- 风险率 22.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多What's Going On With Structure Therapeutics Stock On Wednesday?
Structure Therapeutics shares rose, likely driven by FDA approval of a competing obesity treatment, boosting sentiment.
今天 02:07
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
Structure Therapeutics shares are trading higher after the company announced topline data from the Phase 2 ACCESS clinical program of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity.
Structure Therapeutics shares are trading higher after the company announced to...
03-16 20:50
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
Citizens Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $113
Citizens analyst Jonathan Wolleben maintains Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and lowers the price target from $120 to $113.
02-27 21:49
Structure Therapeutics Q4 Adj. EPS $(0.36) Beats $(0.40) Estimate.
Structure Therapeutics (NASDAQ:GPCR) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.40) by 9.09 percent. This is a 63.64 percent decrease over losses of $(0.22) per share
02-27 06:16
'Structure Therapeutics could be pharma's next buyout candidate'- Axios
https://www.axios.com/pro/biotech-deals/2026/01/30/structure-therapeutics-pharmas-next-buyout-glp1
01-30 23:44
美股大行评级 | 潜在涨幅258.31%！Tempest Therapeutics获HC Wainwright上调评级至"买入"，目标价11美元
今日重点评级关注：HC Wainwright & Co.：上调Tempest Therapeutics评级至"买入"，目标价11美元；Guggenheim：维持Sportradar Gr"买入"评级，目标价从34美元升至35美元
01-23 19:46
